+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Sarcoma Drugs Market by Indication (Angiosarcoma, Chondrosarcoma, Dermatofibrosarcoma Protuberans), Drugs (Chemotherapy Drugs, Immunotherapy Drugs, Targeted Drug Therapy), Sales Channel, End-User - Forecast 2024-2030- Product Image
Global Sarcoma Drugs Market by Indication (Angiosarcoma, Chondrosarcoma, Dermatofibrosarcoma Protuberans), Drugs (Chemotherapy Drugs, Immunotherapy Drugs, Targeted Drug Therapy), Sales Channel, End-User - Forecast 2024-2030- Product Image
Sale

Global Sarcoma Drugs Market by Indication (Angiosarcoma, Chondrosarcoma, Dermatofibrosarcoma Protuberans), Drugs (Chemotherapy Drugs, Immunotherapy Drugs, Targeted Drug Therapy), Sales Channel, End-User - Forecast 2024-2030

  • PDF Icon

    Report

  • 195 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5889758
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Sarcoma Drugs Market size was estimated at USD 1.54 billion in 2023, USD 1.66 billion in 2024, and is expected to grow at a CAGR of 8.10% to reach USD 2.66 billion by 2030.

Sarcoma drugs are a class of medicinal products specifically designed to treat sarcomas, a rare and heterogeneous group of malignant tumors that arise from mesenchymal tissues such as bone, cartilage, fat, muscle, vascular, or hematopoietic cells. Increasing incidence and prevalence of sarcoma worldwide contribute to the rising demand for effective treatment options. Government initiatives supporting cancer research programs financially enable researchers to explore new treatment avenues for rare malignancies such as soft tissue or bone sarcomas. The high cost of developing novel therapies and the subsequent financial burden on healthcare systems can serve as a barrier to widespread adoption. Advancements in research have led to a better understanding of tumor biology and genetics associated with different forms of sarcomas. This knowledge facilitates the development of novel targeted therapies that can precisely attack cancer cells without causing significant harm to healthy tissue. Coupled with ongoing clinical trials investigating innovative approaches such as immunotherapy or gene therapy for treating sarcomas, it further enhances the potential opportunities in this market space.

Regional Insights

The Americas have an advanced sarcoma drugs market due to its well-developed healthcare infrastructure, high awareness about cancer treatment options, and a robust pipeline of investigational drugs. Major pharmaceutical companies are headquartered in the U.S. and have a strong presence in this market. Furthermore, collaboration between government agencies and private firms has resulted in accelerated drug approvals by the U.S. Food and Drug Administration (FDA) and Health Canada. Asia is an emerging market for sarcoma drugs driven by the need for effective drugs to treat the increasing prevalence of soft tissue sarcomas (STS) among its large population base. Countries such as China, India, Japan, South Korea, and Australia are experiencing a rapid increase in R&D for new cancer therapies. Technological advancements, coupled with growing awareness about early diagnosis, have propelled the demand for targeted therapies in this region. Europe showcases a mature market for sarcoma drugs with established players and a strong regulatory framework by the European Medicines Agency (EMA), ensuring that only high-quality medicines reach patients. Furthermore, multiple ongoing clinical trials, collaborations, and partnerships between European pharmaceutical companies and academic research institutions have led to a robust pipeline of investigational drugs in various phases of development.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Sarcoma Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Sarcoma Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Sarcoma Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., AgonOx, Amneal Pharmaceuticals LLC, Aurobindo Pharma Limited, Avacta Life Sciences Limited, Baxter International Inc., Bayer AG, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Ipsen Pharma, Johnson & Johnson Services, Inc., Karyopharm Therapeutics Inc., Lupin Limited, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries Limited, TRACON Pharmaceuticals, Inc., and Viatris Inc.

Market Segmentation & Coverage

This research report categorizes the Sarcoma Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Indication
    • Angiosarcoma
    • Chondrosarcoma
    • Dermatofibrosarcoma Protuberans
    • Epithelioid Sarcoma
    • Kaposi's Sarcoma
    • Leiomyosarcoma
    • Liposarcoma
    • Osteosarcoma
    • Soft Tissue Sarcoma
  • Drugs
    • Chemotherapy Drugs
      • Cisplatin
      • Docetaxel
      • Doxorubicin
      • Etoposide
      • Gemcitabine
      • Ifosfamide
      • Paclitaxel
      • Trabectedin
      • Vincristine
    • Immunotherapy Drugs
      • Atezolizumab
      • Pembrolizumab
    • Targeted Drug Therapy
      • Entrectinib
      • Pazopanib
      • Sorafenib
      • Sunitinib
      • Tazemetostat
  • Sales Channel
    • Offline
      • Hospitals Pharmacies
      • Retail Pharmacies
    • Online
  • End-User
    • Cancer Research Center
    • Homecare
    • Hospital & clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Sarcoma Drugs Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Sarcoma Drugs Market?
  3. What are the technology trends and regulatory frameworks in the Sarcoma Drugs Market?
  4. What is the market share of the leading vendors in the Sarcoma Drugs Market?
  5. Which modes and strategic moves are suitable for entering the Sarcoma Drugs Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Sarcoma Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of sarcoma and the need for effective treatment options
5.1.1.2. Government initiatives encouraging the treatment of sarcoma
5.1.1.3. Favorable government approvals for improved sarcoma drugs
5.1.2. Restraints
5.1.2.1. Limited reimbursements available for sarcoma
5.1.3. Opportunities
5.1.3.1. Ongoing research and development for advanced and new sarcoma drugs
5.1.3.2. Improvements in targeted and immunotherapy approaches for sarcoma
5.1.4. Challenges
5.1.4.1. Issues associated with drug resistance in sarcomas
5.2. Market Segmentation Analysis
5.2.1. Indication: High incidence rates of leiomyosarcoma encouraging new drug development
5.2.2. Drugs: Adoption of targeted sarcoma drugs for more tailored treatment based on individual genetic mutations
5.2.3. Sales Channel: Emerging preference for online sales channel driven by their convenience for home delivery services of prescription medications
5.2.4. End-User: Wide range of drug options to cater to various types and stages of sarcoma patients in hospitals & clinics
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Sarcoma Drugs Market, by Indication
6.1. Introduction
6.2. Angiosarcoma
6.3. Chondrosarcoma
6.4. Dermatofibrosarcoma Protuberans
6.5. Epithelioid Sarcoma
6.6. Kaposi's Sarcoma
6.7. Leiomyosarcoma
6.8. Liposarcoma
6.9. Osteosarcoma
6.10. Soft Tissue Sarcoma
7. Sarcoma Drugs Market, by Drugs
7.1. Introduction
7.2. Chemotherapy Drugs
7.3.1. Cisplatin
7.3.2. Docetaxel
7.3.3. Doxorubicin
7.3.4. Etoposide
7.3.5. Gemcitabine
7.3.6. Ifosfamide
7.3.7. Paclitaxel
7.3.8. Trabectedin
7.3.9. Vincristine
7.3. Immunotherapy Drugs
7.4.1. Atezolizumab
7.4.2. Pembrolizumab
7.4. Targeted Drug Therapy
7.5.1. Entrectinib
7.5.2. Pazopanib
7.5.3. Sorafenib
7.5.4. Sunitinib
7.5.5. Tazemetostat
8. Sarcoma Drugs Market, by Sales Channel
8.1. Introduction
8.2. Offline
8.3.1. Hospitals Pharmacies
8.3.2. Retail Pharmacies
8.3. Online
9. Sarcoma Drugs Market, by End-User
9.1. Introduction
9.2. Cancer Research Center
9.3. Homecare
9.4. Hospital & clinics
10. Americas Sarcoma Drugs Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Sarcoma Drugs Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Sarcoma Drugs Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Award, Recognition, & Expansion
13.3.1.1. Sumitomo Pharma Oncology receives orphan drug designation for Ewing sarcoma treatment
13.3.1.2. FDA approves atezolizumab for alveolar soft part sarcoma in pediatric patients
13.3.1.3. US FDA grants Orphan Drug status to Avacta’s drug for soft tissue sarcoma
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. AbbVie Inc.
14.1.3. AgonOx
14.1.4. Amneal Pharmaceuticals LLC
14.1.5. Aurobindo Pharma Limited
14.1.6. Avacta Life Sciences Limited
14.1.7. Baxter International Inc.
14.1.8. Bayer AG
14.1.9. Bristol-Myers Squibb Company
14.1.10. Daiichi Sankyo Company, Limited
14.1.11. Eisai Co., Ltd.
14.1.12. Eli Lilly and Company
14.1.13. F. Hoffmann-La Roche Ltd.
14.1.14. Fresenius SE & Co. KGaA
14.1.15. GlaxoSmithKline PLC
14.1.16. Hikma Pharmaceuticals PLC
14.1.17. Ipsen Pharma
14.1.18. Johnson & Johnson Services, Inc.
14.1.19. Karyopharm Therapeutics Inc.
14.1.20. Lupin Limited
14.1.21. Merck & Co., Inc.
14.1.22. Novartis AG
14.1.23. Pfizer Inc.
14.1.24. Sumitomo Pharma Co., Ltd.
14.1.25. Sun Pharmaceutical Industries Limited
14.1.26. TRACON Pharmaceuticals, Inc.
14.1.27. Viatris Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. SARCOMA DRUGS MARKET RESEARCH PROCESS
FIGURE 2. SARCOMA DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. SARCOMA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. SARCOMA DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. SARCOMA DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. SARCOMA DRUGS MARKET DYNAMICS
FIGURE 7. SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 8. SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
FIGURE 10. SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
FIGURE 12. SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. SARCOMA DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 14. SARCOMA DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. SARCOMA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. SARCOMA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. SARCOMA DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. SARCOMA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 6. SARCOMA DRUGS MARKET SIZE, BY ANGIOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. SARCOMA DRUGS MARKET SIZE, BY DERMATOFIBROSARCOMA PROTUBERANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. SARCOMA DRUGS MARKET SIZE, BY EPITHELIOID SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. SARCOMA DRUGS MARKET SIZE, BY KAPOSI'S SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 16. SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 18. SARCOMA DRUGS MARKET SIZE, BY CISPLATIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. SARCOMA DRUGS MARKET SIZE, BY DOCETAXEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. SARCOMA DRUGS MARKET SIZE, BY DOXORUBICIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. SARCOMA DRUGS MARKET SIZE, BY ETOPOSIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. SARCOMA DRUGS MARKET SIZE, BY GEMCITABINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. SARCOMA DRUGS MARKET SIZE, BY IFOSFAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. SARCOMA DRUGS MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. SARCOMA DRUGS MARKET SIZE, BY TRABECTEDIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. SARCOMA DRUGS MARKET SIZE, BY VINCRISTINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 29. SARCOMA DRUGS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. SARCOMA DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 33. SARCOMA DRUGS MARKET SIZE, BY ENTRECTINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. SARCOMA DRUGS MARKET SIZE, BY PAZOPANIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. SARCOMA DRUGS MARKET SIZE, BY SORAFENIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. SARCOMA DRUGS MARKET SIZE, BY SUNITINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. SARCOMA DRUGS MARKET SIZE, BY TAZEMETOSTAT, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. SARCOMA DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 41. SARCOMA DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. SARCOMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. SARCOMA DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 45. SARCOMA DRUGS MARKET SIZE, BY CANCER RESEARCH CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. SARCOMA DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. SARCOMA DRUGS MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. CANADA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. CANADA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 75. CANADA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 76. CANADA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 77. CANADA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 78. CANADA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. CANADA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 80. CANADA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. MEXICO SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 82. MEXICO SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 83. MEXICO SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 84. MEXICO SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 85. MEXICO SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 86. MEXICO SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. MEXICO SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 88. MEXICO SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 98. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 100. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 102. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 103. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 105. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 107. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 108. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 109. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 110. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 111. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 112. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 114. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. CHINA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 116. CHINA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 117. CHINA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 118. CHINA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 119. CHINA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 120. CHINA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. CHINA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 122. CHINA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. INDIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 124. INDIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 125. INDIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 126. INDIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 127. INDIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 128. INDIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. INDIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 130. INDIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. INDONESIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. INDONESIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 133. INDONESIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 134. INDONESIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 135. INDONESIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 136. INDONESIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. INDONESIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 138. INDONESIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. JAPAN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. JAPAN SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 141. JAPAN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 142. JAPAN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 143. JAPAN SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 144. JAPAN SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. JAPAN SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 146. JAPAN SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 147. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 149. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 150. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 151. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 152. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 154. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 155. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 156. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 157. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 158. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 159. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 160. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 162. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 164. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 165. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 166. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 167. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 168. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 170. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 171. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 172. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 173. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 174. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 175. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 176. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 178. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. TAIWAN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. TAIWAN SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 181. TAIWAN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 182. TAIWAN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 183. TAIWAN SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 184. TAIWAN SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. TAIWAN SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 186. TAIWAN SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 187. THAILAND SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 188. THAILAND SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 189. THAILAND SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 190. THAILAND SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 191. THAILAND SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 192. THAILAND SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. THAILAND SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 194. THAILAND SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 195. VIETNAM SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 196. VIETNAM SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 197. VIETNAM SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 198. VIETNAM SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 199. VIETNAM SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 200. VIETNAM SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. VIETNAM SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 202. VIETNAM SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 212. DENMARK SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 213. DENMARK SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 214. DENMARK SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 215. DENMARK SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 216. DENMARK SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 217. DENMARK SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. DENMARK SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 219. DENMARK SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 220. EGYPT SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 221. EGYPT SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 222. EGYPT SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 223. EGYPT SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 224. EGYPT SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 225. EGYPT SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. EGYPT SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 227. EGYPT SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 228. FINLAND SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 229. FINLAND SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 230. FINLAND SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 231. FINLAND SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 232. FINLAND SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 233. FINLAND SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. FINLAND SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 235. FINLAND SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 236. FRANCE SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 237. FRANCE SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 238. FRANCE SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 239. FRANCE SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 240. FRANCE SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 241. FRANCE SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. FRANCE SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 243. FRANCE SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 244. GERMANY SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 245. GERMANY SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 246. GERMANY SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 247. GERMANY SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 248. GERMANY SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 249. GERMANY SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 250. GERMANY SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 251. GERMANY SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 252. ISRAEL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 253. ISRAEL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 254. ISRAEL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 255. ISRAEL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 256. ISRAEL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 257. ISRAEL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. ISRAEL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 259. ISRAEL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 260. ITALY SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 261. ITALY SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 262. ITALY SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 263. ITALY SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 264. ITALY SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 265. ITALY SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. ITALY SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 267. ITALY SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 268. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 269. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 270. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 271. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 272. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 273. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 275. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 276. NIGERIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 277. NIGERIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 278. NIGERIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 279. NIGERIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 280. NIGERIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 281. NIGERIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. NIGERIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 283. NIGERIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 284. NORWAY SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 285. NORWAY SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 286. NORWAY SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 287. NORWAY SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 288. NORWAY SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 289. NORWAY SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. NORWAY SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 291. NORWAY SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 292. POLAND SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 293. POLAND SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 294. POLAND SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 295. POLAND SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 296. POLAND SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 297. POLAND SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 298. POLAND SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 299. POLAND SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 300. QATAR SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 301. QATAR SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 302. QATAR SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 303. QATAR SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 304. QATAR SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 305. QATAR SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 306. QATAR SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 307. QATAR SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 308. RUSSIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 309. RUSSIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 310. RUSSIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 311. RUSSIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 312. RUSSIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 313. RUSSIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 314. RUSSIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 315. RUSSIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 316. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 317. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 318. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 319. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 320. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 321. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 322. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 323. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 324. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 325. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 326. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 327. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 328. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 329. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 330. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 331. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 332. SPAIN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 333. SPAIN SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 334. SPAIN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 335. SPAIN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 336. SPAIN SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 337. SPAIN SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 338. SPAIN SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 339. SPAIN SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 340. SWEDEN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 341. SWEDEN SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 342. SWEDEN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 343. SWEDEN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 344. SWEDEN SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 345. SWEDEN SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 346. SWEDEN SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 347. SWEDEN SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 348. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 349. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 350. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 351. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 352. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 353. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 354. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 355. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 356. TURKEY SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 357. TURKEY SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 358. TURKEY SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 359. TURKEY SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 360. TURKEY SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 361. TURKEY SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 362. TURKEY SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 363. TURKEY SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 364. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 365. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 366. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 367. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 368. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 369. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 370. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 371. UNITED ARAB

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • AgonOx
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Limited
  • Avacta Life Sciences Limited
  • Baxter International Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Ipsen Pharma
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • TRACON Pharmaceuticals, Inc.
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages195
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.66 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.66 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Sarcoma Drugs Market Size, Share & Trends Analysis Report By Treatment Type (Chemotherapy, Targeted Therapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Sarcoma Drugs Market Size, Share & Trends Analysis Report By Treatment Type (Chemotherapy, Targeted Therapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 93 Pages
  • Global
From
Sarcoma Drugs Global Market Report 2024 - Product Image

Sarcoma Drugs Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Sarcoma Drugs - Global Strategic Business Report - Product Image

Sarcoma Drugs - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Sarcoma Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Sarcoma Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 170 Pages
  • Global
From
Ewing Sarcoma Drugs Market - Global Ewing Sarcoma Drugs Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 - Product Image

Ewing Sarcoma Drugs Market - Global Ewing Sarcoma Drugs Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030

  • Report
  • 280 Pages
  • Global

About the Sarcoma Drug Market

Sarcoma is a type of cancer that affects the connective tissues of the body, such as muscle, bone, fat, and blood vessels. Sarcoma drugs are used to treat this type of cancer, and are part of the larger oncology drug market. These drugs are typically used in combination with other treatments, such as surgery, radiation, and chemotherapy. Sarcoma drugs are designed to target the specific type of cancer, and can be used to reduce the size of tumors, slow the growth of cancer cells, and reduce the risk of metastasis. The sarcoma drug market is highly competitive, with many companies developing new treatments and therapies. Some of the major players in the market include Pfizer, Merck, Novartis, Bristol-Myers Squibb, and Eli Lilly. Other companies, such as Amgen, AstraZeneca, and Celgene, are also developing treatments for sarcoma. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.